ACR Releases 2024 Guideline Summary for Lupus Nephritis
Nov 25, 2024 · The American College of Rheumatology (ACR) has released a summary of a new guideline for the screening, treatment, and management of lupus nephritis (LN), emphasizing prompt diagnosis, personalized treatment approaches, and …
TNX-102 SL Reduces Fibromyalgia Pain, Improves Sleep and …
Nov 15, 2024 · Additionally, FIQR Symptoms (P =.000002) and Function (P =.001) scores, PROMIS Sleep Disturbance (P =.0000001) and Fatigue (P =.00009) scores, and sleep quality measures (P =.0007) improved with TNX-102 SL treatment.Compared with placebo, TNX-102 SL also appeared to improve sexual function among women, according to total Changes in …
FDA Roundup: Rheumatology Drug Alerts 2024
Mar 5, 2024 · Throughout 2024, the United States Food and Drug Administration (FDA) approved new drugs for the treatment of osteoporosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), giant cell arteritis, Duchenne muscular dystrophy (DMD), and certain cancers, while also expanding treatment indications for previously approved drugs.
SGLT2 Inhibitors Linked to Lower Rhabdomyolysis Risk in Statin …
Dec 30, 2024 · The study included 222,187 statin users, including 2928 cases of rhabdomyolysis and 14,640 matched control participants (mean age, 79.1 years; 43.5% female).
Slow Response to Tirzepatide Allows Longer Treatment Duration
May 30, 2024 · The proportions of slow responders who lost at least 5% of their body weight were 70% at week 24 and 90% at week 72. Among slow responders, the mean (SD) time to achieve at least 5% body weight reduction was 24.8 (12.7) weeks.
Ehlers-Danlos Syndrome - Rheumatology Advisor
Aug 10, 2022 · Ehlers-Danlos syndrome is a group of inherited connective tissue disorders that primarily affects the skin, joints, and blood vessel walls1 but can affect every organ system and result in significant morbidity and mortality. Typical clinical manifestations are skin hyperelasticity, hypermobility of joints, the fragility of blood vessels, and atrophic scarring. Hypermobility …
FDA to Review Sublingual Cyclobenzaprine for Fibromyalgia …
Dec 30, 2024 · The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.
Rare and Unusual Clinical Presentations of Gout
Apr 19, 2024 · Gout is a type of inflammatory arthritis characterized by the deposition of monosodium urate crystals and the formation of tophi in tissues, typically in or around the joints. 1 Gout occurs more commonly in men compared with women 2 and “usually presents with sudden onset of severe pain, redness, and swelling of a single joint, most often in the feet, ankle, or …
Exploring the Oral Manifestations of Rheumatic Diseases
Sep 13, 2024 · References: Kiernan Y, O’Connor C, Ryan J, Murphy M. Oral health in patients with severe inflammatory dermatologic and rheumatologic disease. Skin Health Dis.Published online August 7, 2022. doi:10.1002/ski2.156; Konig MF, Abusleme L, Reinholdt J, et al. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection …
Undifferentiated Connective Tissue Disease - Rheumatology Advisor
Aug 9, 2022 · Undifferentiated connective tissue disease (UCTD) is a diagnosis of exclusion. Patients who present with clinical and serolotical manifestations that suggest a systemic autoimmune disease but do not fulfill criteria for defined connective tissue disease (eg, systemic lupus erythematosus, scleroderma, myositis, rheumatoid arthritis, Sjogren's syndrome) are …